Fulgent Genetics, Inc. (FLGT)
| Market Cap | 2.32B |
| Revenue (ttm) | 909.74M |
| Net Income (ttm) | 493.45M |
| Shares Out | 29.15M |
| EPS (ttm) | 17.59 |
| PE Ratio | 4.44 |
| Forward PE | 20.92 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 680,274 |
| Open | 79.58 |
| Previous Close | 78.67 |
| Day's Range | 75.66 - 80.08 |
| 52-Week Range | 30.05 - 189.89 |
| Beta | 1.49 |
| Analysts | Hold |
| Price Target | 141.00 (+80.7%) |
| Est. Earnings Date | Nov 8, 2021 |
About FLGT
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves insurance, hospitals, and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for FLGT stock is "Hold." The 12-month stock price forecast is 141.00, which is an increase of 80.72% from the latest price.
News
3 Top Healthcare Stocks to Buy Right Now
Each has its own reason for being in your portfolio.
Is FULGENT GENETIC (FLGT) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...
What's Going on With Fulgent Genetics?
The company is leveraging success with its COVID-19 tests to position itself better for a post-pandemic world.
Where to Invest $5,000 Right Now
An investment in one or both of these high-growth companies could generate stellar returns.
Can This Stock Grow Despite a COVID Testing Decline?
Fulgent has capitalized on COVID-19 testing, but even though this segment of its business might slow, there are plenty of reasons to own the company.
These 3 Top Healthcare Stocks Are Screaming Buys Right Now
If the market crashes these companies could be insulated.
Fulgent Genetics to Partner with Houston Health Department and Houston-Area Public Schools on Back-to-School COVID-19...
TEMPLE CITY, Calif.--(BUSINESS WIRE)---- $FLGT--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient care in onc...
3 Unstoppable Healthcare Stocks to Buy With Just $1,000
It doesn't take much when you buy great companies and let them grow.
3 Top Healthcare Stocks You Can Buy for $100 or Less
It doesn't take a lot of upfront cash to add one of these stocks to your portfolio.
10 Million Reasons I'm Not Selling Fulgent Genetics
The company is about to shock Wall Street.
Labcorp and 4 Other Stocks Can Boast Value and Momentum
Twice a year in this column, I hunt for stocks that seem to possess both value and momentum. Even though the market has hit records lately, it's still possible to find stocks that have both qualities.
Have $500? 3 Absurdly Cheap Healthcare Stocks Long-Term Investors Should Consider Buying Right Now
Everyone loves a discount.
New Strong Sell Stocks for August 17th
ACCD, CHRS, ELVT, FLGT, and GSHD have been added to the Zacks Rank #5 (Strong Sell) List on August 17, 2021.
2 Types of Growth Stocks Investors Should Be Holding in Their Portfolios Today
Hedging against COVID-19 could prove to be crucial in keeping your portfolio safe.
Why Shares of Fulgent Genetics Are Plunging Today
Spectacular quarterly results were not enough to satisfy investors' appetites.
Fulgent Genetics Stock Falls As Q2 Earnings Miss Street Estimates; Lowers FY21 Sales Outlook
Fulgent Genetics Inc (NASDAQ: FLGT) reported after the close of the market on Monday that its second-quarter revenues increased nearly ninefold, driven primarily by increased test volumes. Revenues skyr...
FULGENT GENETIC (FLGT) Q2 Earnings and Revenues Miss Estimates
FULGENT GENETIC (FLGT) delivered earnings and revenue surprises of -0.78% and -21.06%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Fulgent Genetics Reports Second Quarter Financial Results
TEMPLE CITY, Calif.--(BUSINESS WIRE)---- $FLGT--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “company”), a technology-based genetic testing company focused on transforming patient care in onc...
Fulgent Genetics and Helio Health Announce Strategic Partnership to Commercialize Early Cancer Detection Tests
TEMPLE CITY, Calif. & IRVINE, Calif.--(BUSINESS WIRE)---- $FLGT--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming pa...
Fulgent Genetics Announces Acquisition of CSI Laboratories
TEMPLE CITY, Calif.--(BUSINESS WIRE)---- $FLGT--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient care in onc...
FULGENT GENETIC (FLGT) Gains But Lags Market: What You Should Know
In the latest trading session, FULGENT GENETIC (FLGT) closed at $110.87, marking a +0.33% move from the previous day.
What's in Store for Fulgent Genetics (FLGT) in Q2 Earnings?
Fulgent Genetics' (FLGT) Q2 results are likely to reflect growth in areas like adult neurogenetics, hereditary cancer, hereditary cardiovascular genetics, reproductive health and sequencing as a service.
FULGENT GENETIC (FLGT) Reports Next Week: Wall Street Expects Earnings Growth
FULGENT GENETIC (FLGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FULGENT GENETIC (FLGT) Gains As Market Dips: What You Should Know
In the latest trading session, FULGENT GENETIC (FLGT) closed at $92.25, marking a +0.36% move from the previous day.